Overview:
Thebaine is an opiate alkaloid extracted from the papaver somniferous and papaver bracteatum poppy plants. Thebaine is also known as codeine, methyl enol ether, and paramorphine. It is available as a minor constituent in the range of 0.2–1.5% in the opium poppy and has a structural configuration similar to morphine and codeine. Its physical properties are that it is a crystalline, white substance that is slightly soluble in water. Thebaine is a more lethal substance than morphine. Therefore it is categorized as a poisonous alkaloid. The major producers of thebaine from opium poppies are Australia, Spain, France, and Hungary; together, they produce 90% of thebaine globally. The pharmacodynamics of thebaine is that it has a stimulatory effect by acting on the opioid receptors present in the central nervous system, whereas morphine and codeine have a depressant effect. If ingested at high doses, it results in convulsions similar to strychnine toxication.
According to the data presented by the International Narcotics Control Board, the estimated area involved in the cultivation of opium poppy rich in thebaine is 16,800 hectares. Thebaine is classified as a Schedule II substance under the Analog Act of the United States and the Controlled Substances Act of international law. It is classified as a Class A drug under the Misuse of Drugs Act 1971 in Great Britain. Thebaine, as such, does not find any medicinal use but is employed as a raw material or lead substance for the industrial synthesis of opiate narcotics such as nalbuphine, naltrexone, naloxone, oxymorphone, oxycodone, buprenorphine, and other narcotic drugs that find therapeutic use. Major companies such as Noramco and Tasmanian alkaloids are actively engaged in the cultivation of the varieties Papaver somniferum and Papaver bracteatum to extract industrial-grade thebaine. They work in collaboration with the customers to provide thebaine with the highest level of efficiency, purity, and supply security.
The global thebaine market is classified as follows:
Applications
-
- Nalbuphine
- Naltrexone
- Naloxone
- Oxymorphone
- Oxycodone
- Buprenorphine
- Others
Geography
- North America
- United States
- Canada
Europe
- United Kingdom
- Germany
- Rest of Europe
Asia Pacific
- Japan
- China
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- rest of Latin America
Middle East and Africa
- GCC
- Rest of the Middle East and Africa
Key players identified for the global thebaine market include:
The prominent players in the global thebaine market are API Labs, Inc., Alcaliber S.A., CEPiA Sanofi, Faran Shimi Pharmaceutical Co., Mallinckrodt Pharmaceuticals, Noramco (Johnson & Johnson), TPI, and Tasmanian Alkaloids (S.K. Capital Partners).
This report offers the following:
- A precise summary of the scope of the global thebaine market is as follows:
- In the scope of the report, historical information for 2015 is given, which is helpful in identifying the trends prevalent in the Theban market for the duration of 2015-2025 and the forecast period of 2017-2025.
- The market assessment for the respective segments is done and provided with their respective compound annual growth rates.
- Attractive investment propositions are depicted by geography and the top three countries based on market size and compound annual growth rate.
- The competitive landscape is elucidated to understand the competitive milieu in the thebaine market by mapping the product portfolio, inception, and geographical presence of the prominent players existing in the thebaine market.
- Company profiles for the major players are highlighted, along with their business descriptions, financial information, product portfolio, and recent news coverage.
